Phase 2 Prostate Cancer Trial, Recruiting NCT06922318 Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06922318
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with prostate cancer (a specific type called adenocarcinoma, confirmed by a tissue sample)
  • You are physically able to carry out basic daily activities, with only mild limitations at most (confirm with trial site)
  • You are receiving ongoing hormone therapy to lower testosterone, either through surgery or medication
  • Your testosterone blood level is very low (below 50 ng/dl)
  • Your cancer has spread to other parts of the body, confirmed by a CT scan or bone scan
  • Your cancer has gotten worse while you were taking a newer type of hormone-blocking drug (such as Abiraterone, Enzalutamide, Darolutamide, or Apalutamide), shown by rising PSA levels or imaging scans
  • Your PSA level at screening is at least 1.0 ng/mL
  • If you have a tumor that can be safely biopsied, you must agree to provide tissue samples before and during treatment
  • You have stopped taking your second-generation hormone-blocking drug for at least 2 weeks before starting the trial
  • Certain previous treatments are allowed, as long as your last dose was more than 4 weeks ago (including some vaccines, chemotherapy, radiation, and other prostate cancer drugs)
  • Your liver, kidney, and blood counts are within acceptable ranges based on blood tests
  • You are willing and able to understand and sign a consent form
  • If you are sexually active with a partner who could become pregnant, you agree to use reliable contraception throughout the study and for at least 3 months after your last dose, and you agree not to donate sperm during this time
  • If your partner is pregnant or breastfeeding, you agree to either abstain from sex or use a condom every time

Who may not be able to join:

  • You have significant pain from your cancer that requires opioid (strong prescription) pain medicines
  • Your overall health and ability to function are severely limited (confirm with trial site)
  • You need to use a self-inserted urinary catheter to urinate because of a blockage caused by prostate cancer or an enlarged prostate (note: a permanently placed catheter may still be acceptable — confirm with trial site)
  • You have an active, uncontrolled infection (some people with HIV, hepatitis B, or hepatitis C may still be eligible under certain conditions — confirm with trial site)
  • You have a physical or mental condition that would make it difficult to safely take part in or understand the study
  • You are currently taking the blood thinners warfarin, rivaroxaban, or apixaban — unless you are able to switch to an alternative blood thinner before starting (confirm with trial site)
  • You had a blood clot event in the past 12 months and are not currently on blood-thinning medication
  • You have a red blood cell level that is too high, untreated severe sleep apnea, or poorly controlled heart failure
  • You are allergic to sesame seed oil or cottonseed oil
  • You have had major surgery within the past 3 weeks, or have not fully healed from a previous surgery
  • You have a history of seizures, or have a condition that may increase your risk of seizures (such as a prior stroke affecting the brain, significant brain injury, or a brain blood vessel abnormality)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Samuel Denmeade, MD, Johns Hopkins University

Phone: 410-733-3232

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 August 2025
Est. completion
30 August 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clinical/radiographic progression free survival (PFS) with BATZEN; Prostate specific antigen (PSA)-Progression free survival (PFS) with ZENZA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov